UMBC researchers reported that ovarian cancer cells depend on the USP15 enzyme, with USP15 reduction slowing tumor growth, disrupting cell division, limiting spread, and increasing sensitivity to chemotherapy. The study positions USP15 as a potential therapeutic vulnerability that could be paired with existing cytotoxic regimens.